


**Figure S1: Immune-marker expression of A(H1N1)pdm09-specific CD4<sup>+</sup> T-cell responses (Study A).** Adults 18-60 years of age received AS03-adjuvanted A(H1N1)pdm09 ('H1N1') vaccine containing 3.75 µg hemagglutinin (HA), or non-adjuvanted H1N1 vaccine containing 15 µg HA, at Day (D) 0 and D21. Data for the per-protocol cohort at Month (M) 12 are reported as percentages of A(H1N1)pdm09-specific CD4<sup>+</sup> T cells expressing at least the indicated immune marker and another, among interferon-gamma (IFN-γ), interleukin-2 (IL-2), tumor necrosis factor-alpha (TNF-α), and CD40L per million CD4<sup>+</sup> T cells, with medians, first and third quartiles and the minimum/maximum values measured, after stimulation with H1N1 split antigen. Data for D0 and D42 supplements previously published data for the cohort evaluated in terms of CD4<sup>+</sup> T cells expressing at least 2 immune markers (1).



## References

1. **Roman F, Clément F, Dewé W, Walravens K, Maes C, Willekens J, De Boever F, Hanon E, Leroux-Roels G.** 2011. Effect on cellular and humoral immune responses of the AS03 Adjuvant System in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. *Clin Vaccine Immunol* **18**:835-843.